IP Library › Granted Patent US 12,410,253
Granted Patent B2
US 12,410,253 · App. 18/477,113 · Granted Sep 9, 2025

Compositions comprising anti-NRP2 antibodies

Inventors: Luke Burman (San Diego, CA); Yeeting Chong (San Diego, CA); Leslie Ann Greene (San Diego, CA); David King (Encinitas, CA); Zhiwen Xu (La Jolla, CA); Ryan Andrew Adams (San Diego, CA)
Assignee: aTyr Pharma, Inc.
C07K16/2863A61K39/3955A61P35/04A61K39/001103A61K2039/505C07K2317/24C07K2317/33C07K2317/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,410,253
App. No.
18/477,113
Granted
Sep 9, 2025
Kind
B2
Abstract

Provided are affinity matured and humanized antibodies and antigen-binding fragments thereof that specifically bind to human neuropilin-2 (NRP2) polypeptides, including those that modulate binding interactions between human NRP2 and at least one NRP2 ligand, and which thereby modulate subsequent NRP2-mediated downstream signaling events, including related therapeutic compositions and methods for modulating NRP2 activity and treating diseases such as NRP2-associated diseases.

Claims (25)

1. A therapeutic composition, comprising a pharmaceutically-acceptable carrier and at least one antibody or antigen-binding fragment thereof that specifically binds to a human neuropilin-2 (NRP2) polypeptide at an epitope in the neuropilin a2 domain of human NRP2, wherein the at least one antibody or antigen-binding fragment thereof comprises:

a heavy chain variable region (V H ) sequence that comprises complementary determining region V H CDR1, V H CDR2, and V H CDR3 sequences; and a light chain variable region (V L ) sequence that comprises complementary determining region V L CDR1, V L CDR2, and V L CDR3 sequences, wherein:

the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 31-33, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 34-36, respectively; or

the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 37-39, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 40-42, respectively,

including variants thereof that differ by substitution of one amino acid in V H CDR3, V L CDR1 and/or V L CDR3, wherein the V H CDR3 sequence comprises SEQ ID NO: 81, the V L CDR1 sequence comprises SEQ ID NO: 82, and the V L CDR3 sequence comprises SEQ ID NO: 83, wherein X5 of SEQ ID NO: 83 is F, G, I, K, L, N, R, T, V, or Y.

2. The therapeutic composition of claim 1 , wherein:

the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 31-33, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 34-36, respectively; or

the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 37-39, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 40-42, respectively.

3. The therapeutic composition of claim 2 , wherein:

the V H sequence comprises a sequence at least 95% identical to a SEQ ID NO: 53, and the V L sequence comprises a sequence at least 95% identical to SEQ ID NO: 54; or

the V H sequence comprises a sequence at least 95% identical to SEQ ID NO: 55, and the V L sequence comprises a sequence at least 95% identical to SEQ ID NO: 56.

4. The therapeutic composition of claim 3 , wherein:

the V H sequence comprises SEQ ID NO: 53, and the V L sequence comprises SEQ ID NO: 54; or

the V H sequence comprises SEQ ID NO: 55, and the V L sequence comprises SEQ ID NO: 56.

5. The therapeutic composition of claim 1 , wherein the at least one antibody or antigen-binding fragment thereof comprises an IgA (including subclasses IgA1 and IgA2), IgD, IgE, IgG (including subclasses IgG1, IgG2, IgG3, and IgG4), or IgM Fc domain, or variant thereof, optionally wherein the Fc domain is a human Fc domain.

6. The therapeutic composition of claim 5 , wherein the at least one antibody or antigen-binding fragment thereof comprises an IgG1 or IgG3 Fc domain.

7. The therapeutic composition of claim 5 , wherein the at least one antibody or antigen-binding fragment thereof comprises an IgG2 or IgG4 Fc domain.

8. The therapeutic composition of claim 5 , wherein the at least one antibody or antigen-binding fragment thereof comprises an IgG1 or IgG4 Fc domain, optionally selected from SEQ ID NOs: 144-147.

9. The therapeutic composition of claim 1 , wherein the at least one antibody or antigen-binding fragment thereof comprises a modified IgG1 or IgG4 Fc domain which has altered binding to FcRn, optionally wherein the modified IgG1 or IgG4 Fc domain comprises any one or more of YD (M252Y/T256D), DQ (T256D/T307Q), DW (T256D/T307W), YTE (M252Y/S254T/T256E), AAA (T307A/E380A/N434A), LS (M428L/N434S), M252Y, T256D/E, K288D/N, T307Q/W, E380C, N434F/Y, and/or Y436H/N/W mutations (EU numbering).

10. The therapeutic composition of claim 1 , wherein the at least one antibody or antigen-binding fragment thereof is a monoclonal antibody and/or a humanized antibody.

11. The therapeutic composition of claim 1 , wherein the at least one antibody or antigen-binding fragment thereof is an Fv fragment, a single chain Fv (scFv) polypeptide, or a minibody.

12. The therapeutic composition of claim 1 , wherein the composition has a purity of at least about 80% on a protein basis with respect to the at least one antibody or antigen-binding fragment, and is substantially aggregate-free.

13. The therapeutic composition of claim 12 , wherein the therapeutic composition is substantially endotoxin-free.

14. The therapeutic composition of claim 1 , wherein the therapeutic composition is a sterile, injectable solution, optionally suitable for intravenous, intramuscular, subcutaneous, or intraperitoneal administration.

15. The therapeutic composition of claim 1 , which is a concentrated lyophilized composition.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2023
From: BURMAN, LUKE; CHONG, YEETING; GREENE, LESLIE ANN; KING, DAVID; XU, ZHIWEN; ADAMS, RYAN ANDREW
To: ATYR PHARMA, INC.
Reel/Frame 065500/0024 →
Continuity (4)
Division 17062100 · Oct 2, 2020
Provisional Application 63024960 · May 14, 2020
Provisional Application 62910042 · Oct 3, 2019
Related Publication 20240092917A1 · Mar 21, 2024
References Cited (228)
US 6428965B1 · Ginty et al. · 2002 [cited by applicant]
US 7736655B2 · Klagsbrun et al. · 2010 [cited by applicant]
US 8318163B2 · Appleton et al. · 2012 [cited by applicant]
US 8466264B2 · Appleton et al. · 2013 [cited by applicant]
US 8529905B2 · Klagsbrun et al. · 2013 [cited by applicant]
US 8648173B2 · Wu et al. · 2014 [cited by applicant]
US 8722043B2 · Borg et al. · 2014 [cited by applicant]
US 8920805B2 · Wu et al. · 2014 [cited by applicant]
US 8956622B2 · Bagnard et al. · 2015 [cited by applicant]
US 11505610B2 · Burman et al. · 2022 [cited by applicant]
US 11767520B2 · Mendlein et al. · 2023 [cited by applicant]
US 11807687B2 · Burman et al. · 2023 [cited by applicant]
US 12065495B2 · Burman et al. · 2024 [cited by applicant]
US 20020127227A1 · Holmes et al. · 2002 [cited by applicant]
US 20030045691A1 · Ono et al. · 2003 [cited by applicant]
US 20030088075A1 · Shitara et al. · 2003 [cited by applicant]
US 20030113324A1 · Alitalo et al. · 2003 [cited by applicant]
US 20040005647A1 · Denardo et al. · 2004 [cited by applicant]
US 20040028685A1 · Kinch et al. · 2004 [cited by applicant]
US 20040038339A1 · Kufer et al. · 2004 [cited by applicant]
US 20040214766A1 · Alitalo et al. · 2004 [cited by applicant]
US 20050064518A1 · Albone et al. · 2005 [cited by applicant]
US 20060280747A1 · Fuh et al. · 2006 [cited by applicant]
US 20070189962A1 · Pastan et al. · 2007 [cited by applicant]
US 20090196850A1 · Romagne et al. · 2009 [cited by applicant]
US 20100130904A1 · Kirber · 2010 [cited by applicant]
US 20100172921A1 · Wu et al. · 2010 [cited by applicant]
US 20100310573A1 · Nakagawa et al. · 2010 [cited by applicant]
US 20110064670A1 · Gogineni et al. · 2011 [cited by applicant]
US 20110091377A1 · Alani et al. · 2011 [cited by applicant]
US 20110091384A1 · Alani et al. · 2011 [cited by applicant]
US 20110243932A1 · Barrett et al. · 2011 [cited by applicant]
US 20120027779A1 · Borg et al. · 2012 [cited by applicant]
US 20120282637A1 · Huber et al. · 2012 [cited by applicant]
US 20130131319A1 · Igawa et al. · 2013 [cited by applicant]
US 20130266517A1 · Saldanha et al. · 2013 [cited by applicant]
US 20140193420A1 · Aburatani et al. · 2014 [cited by applicant]
US 20140234312A1 · Wu et al. · 2014 [cited by applicant]
US 20150030600A1 · Marks et al. · 2015 [cited by applicant]
US 20150218267A1 · Brodeur et al. · 2015 [cited by applicant]
US 20150307589A1 · Bagnard et al. · 2015 [cited by applicant]
US 20160000873A1 · Long et al. · 2016 [cited by applicant]
US 20160017041A1 · Violette et al. · 2016 [cited by applicant]
US 20160046711A1 · Bialucha et al. · 2016 [cited by applicant]
US 20160108113A1 · Ayalon et al. · 2016 [cited by applicant]
US 20160108131A1 · Berne et al. · 2016 [cited by applicant]
US 20160312300A1 · Alani et al. · 2016 [cited by applicant]
US 20170100456A1 · Briscoe et al. · 2017 [cited by applicant]
US 20180193454A1 · Rothstein et al. · 2018 [cited by applicant]
US 20180282402A1 · Adams et al. · 2018 [cited by applicant]
US 20190309076A1 · Burman et al. · 2019 [cited by applicant]
US 20210163606A1 · Burman et al. · 2021 [cited by applicant]
US 20230312730A1 · Burman et al. · 2023 [cited by applicant]
US 20240417476A1 · Burman et al. · 2024 [cited by applicant]
US 20250074990A1 · Burman et al. · 2025 [cited by applicant]
CN 1726226A · 2006 [cited by applicant]
CN 101326196A · 2008 [cited by applicant]
CN 101743253A · 2010 [cited by applicant]
CN 101754771A · 2010 [cited by applicant]
CN 102597776A · 2012 [cited by applicant]
CN 102667484A · 2012 [cited by applicant]
CN 103459422A · 2013 [cited by applicant]
CN 104203268A · 2014 [cited by applicant]
CN 105407891A · 2016 [cited by applicant]
EP 1968565B1 · 2015 [cited by applicant]
EP 3024460B1 · 2020 [cited by applicant]
JP 2010527350A · 2010 [cited by applicant]
JP 2012500832A · 2012 [cited by applicant]
JP 2013507641A · 2013 [cited by applicant]
WO WO9929729A2 · 1999 [cited by applicant]
WO WO9929858A1 · 1999 [cited by applicant]
WO WO9930157A2 · 1999 [cited by applicant]
WO WO2004035537A2 · 2004 [cited by applicant]
WO WO2007020075A1 · 2007 [cited by applicant]
WO WO2007056470A2 · 2007 [cited by applicant]
WO WO2007095749A1 · 2007 [cited by applicant]
WO WO2008143665A1 · 2008 [cited by applicant]
WO WO2008143666A2 · 2008 [cited by applicant]
WO WO2009043933A1 · 2009 [cited by applicant]
WO WO2010065940A1 · 2010 [cited by applicant]
WO WO2010102251A2 · 2010 [cited by applicant]
WO WO2010119704A1 · 2010 [cited by applicant]
WO WO2011032013A1 · 2011 [cited by applicant]
WO WO2011047033A2 · 2011 [cited by applicant]
WO WO2012069557A1 · 2012 [cited by applicant]
WO WO2013106765A1 · 2013 [cited by applicant]
WO WO2013116742A1 · 2013 [cited by applicant]
WO WO2014105810A1 · 2014 [cited by applicant]
WO WO2015136471A1 · 2015 [cited by applicant]
WO WO2017205377A2 · 2017 [cited by applicant]
WO WO2018102589A2 · 2018 [cited by applicant]
WO WO2018195302A1 · 2018 [cited by applicant]
WO WO2019075472A1 · 2019 [cited by applicant]
WO WO2019086351A1 · 2019 [cited by applicant]
WO WO2019147973A1 · 2019 [cited by applicant]
WO WO2019195770A1 · 2019 [cited by applicant]
WO WO2020200196A1 · 2020 [cited by applicant]
WO WO2021058548A1 · 2021 [cited by applicant]
WO WO2021067761A1 · 2021 [cited by applicant]
WO WO2021202590A1 · 2021 [cited by applicant]
WO WO2023063208A1 · 2023 [cited by applicant]
WO WO2023076998A1 · 2023 [cited by applicant]
WO WO2023245117A2 · 2023 [cited by applicant]
Herold et al., Determinants of the assembly and function of antibody variable domains, Scientific Reports, 7:12276, DOI: 10.1038/s41598-017-12519-9, 17 pages, Sep. 2017. [cited by examiner]
Sela-Culang et al., The structural basis of antibody-antigen recognition, Front. Immunol. 4:302, 13 pages, Oct. 2013. [cited by examiner]
Qiu et al., Engineering an anti-CD52 antibody for enhanced deamidation stability, mAbs, 11(7):1266-1275, 2019. [cited by examiner]
Alto, L. T. et al., “Semaphorins and their signaling mechanisms,” Methods. Mol. Biol. 1493:1-25 (2017). [cited by applicant]
Anonymous, “aTyr Pharma Presents Preclinical Research Characterizing Effects of ATYR2810 in Highly Aggressive Tumor Subtypes at the 2022 AACR Annual Meeting : BioSpace,” Apr. 11, 2022, 3 pages, Retrieved from the Intern… [cited by applicant]
Appleton, B. A. et al., “Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding,” The EMBO Journal, 26(23):4902-4912 (Nov. 2007). [cited by applicant]
Aung, N. Y. et al., “Specific neuropilins expression in alveolar macrophages among tissue-specific macrophages,” PLoS One 11(2): pp. e0147358 (2016). [cited by applicant]
Bannerman, P. et al., “Peripheral nerve regeneration is delayed in neuropilin 2-deficient mice,” J. Neurosci. Res. 86(14):3163-3169 (2008). [cited by applicant]
Bielenberg, D. R. et al., “Increased smooth muscle contractility in mice deficient for neuropilin 2,” Am. J. Path. 181(2):548-559 (2012). [cited by applicant]
Bielenberg, D. R. et al., “Neuropilins in neoplasms: Expression, regulation, and function,” Exp. Cell. Res. 312:584-593 (2006). [cited by applicant]
Binch, A. L. A. et al., “Class 3 semaphorins expression and association with innervation and angiogenesis within the degenerate human intervertebral disc,” Oncotarget 6(21):18338-18354 (2015). [cited by applicant]
Bogan and Thorn, “Anatomy of hot spots in protein interfaces”, J Mol Biol. Jul. 3, 1998; 280(1): 1-9. [cited by applicant]
Boscolo, E. et al., “AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation,” Angiogenesis 18(2):151-162 (2015). [cited by applicant]
Cao, Y. et al., “Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial 5 integrin,” Cancer. Res. 73(14):4579-4590 (2013). [cited by applicant]
Casset, F., et al., “A Peptide Mimetic of an Anti-cd4 Monoclonal Antibody by Rational Design,” Biochemical and Biophysical Research Communications, Jul. 2003, vol. 307 (1), pp. 198-205. [cited by applicant]
Caunt, M. et al., “Blocking neuropilin-2 function inhibits tumor cell metastasis,” Cancer Cell, vol. 13, No. 4, Apr. 2008, pp. 331-342. [cited by applicant]
Chen, L. et al., “131I-labeled monoclonal antibody targeting neuropilin receptor type-2 for tumor SPECT imaging,” Int. J. Oncol. 50:649-659 (2017). [cited by applicant]
Chen, Y., et al., “Selection and Analysis of an Optimized Anti-vegf Antibody: Crystal Structure of an Affinity-matured Fab in Complex With Antigen,” Journal of Molecular Biology, Nov. 1999, vol. 293 (4), pp. 865-881. [cited by applicant]
Chong, Y. E. et al., “ATYR2810, a Neuropilin-2 antibody, selectively blocks the NRP2/VEGFR signaling axis and sensitizes aggressive cancers to chemotherapy,” Jan. 2021, Retrieved from the Internet: URL: https://atyrphar… [cited by applicant]
Corliss, B. A. et al., “Macrophages: An inflammatory link between angiogenesis and lymphangiogenesis,” Microcirculation 23(2):95-121 (2016). [cited by applicant]
De Pascalis et al., “Grafting of ‘Abbreviated’ Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody,” … [cited by applicant]
Dong, X. et al., “Elevated expression of neuropilin-2 associated with unfavorable prognosis in hepatocellular carcinoma,” OncoTargets and Therapy 10:3827-3833 (2017). [cited by applicant]
Drabkin, H. A. et al., “A triad of NRP2, DLX and p53 proteins in lung cancer metastasis,” Oncotarget 8(57):96464-96465 (2017). [cited by applicant]
Dutta, S. et al., “Neuropilin-2 regulates endosomal maturation and EGFR trafficking to support cancer cell pathobiology,” Cancer Res. 76(2):418-428 (2016). [cited by applicant]
Elaimy, A. L. et al., “VEGF-neuropilin-2 signaling promotes stem-like traits in breast cancer cells by TAZ-mediated repression of the Rac GAP 2-chimaerin,” Sci. Signal 11, pp. eaao6897 (2018). [cited by applicant]
Elpek, G. O., “Neuropilins and liver,” World J. Gastroent. 21(23):7065-7073 (2015). [cited by applicant]
Extended European Search Report for European Application No. 19781711.7, mailed Dec. 16, 2021, 11 pages. [cited by applicant]
Fassold, A. et al., “Soluble neuropilin-2, a nerve repellent receptor, is increased in rheumatoid arthritis synovium and aggravates sympathetic fiber repuslion and arthritis,” Arthritis & Rheum. 60(10):2892-2901 (2009). [cited by applicant]
Forsyth et al., “Deep mutational scanning of an antibody against epidermal growth factor receptor using mammalian cell display and massively parallel pyrosequencing”, mAbs. Jul.-Aug. 2013; 5(4): 523-32. Epub May 29, 201… [cited by applicant]
Fujita, H. et al., “Expressions of neuropilin-1, neuropilin-2 and semaphorin 3A Mrna in the rat brain after middle cerebral artery occlusion,” Brain Research 914(1-2):1-14 (2001). [cited by applicant]
Fusco, F. et al., “Progressive bladder remodeling due to bladder outlet obstruction: a systematic review of morphological and molecular evidences in humans,” BMC Urology 18:1-11 (2018). [cited by applicant]
Gemmill, R. M. et al., “The neuropilin 2 isoform NRP2b uniquely supports TGF-mediated progression in lung cancer,” Sci. Signal. 10, pp. eaag0528 (2017). [cited by applicant]
Goel, H. L. et al., “Enhancing integrin function by VEGF/neuropilin signaling,” Cell Adhesion & Migration, 6(6):554-560 (2012). [cited by applicant]
Goel, H. L. et al., “GLI1 regulates a novel neuropilin-2/61 integrin based autocrine pathway that contributes to breast cancer initiation,” EMBO Mol. Med. 5:488-508 (2013). [cited by applicant]
Goel, H. L. et al., “VEGF/Neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-1R define a novel mechanism of aggressive prostate cancer,” Cancer Discov. 2(10):906-921 (2012). [cited by applicant]
Gogineni, A. et al., “Inhibition of VEGF-C modulates distal lymphatic remodeling and secondary metastasis,” PloS One 8(7):pp. e68755 (2013). [cited by applicant]
Grandclement, C. et al., “Neuropilin-2 Expression Promotes TGF-1-Mediated Epithelial to Mesenchymal Transition in Colorectal Cancer Cells,” PLoS One 6(7):pp. e20444 (2011). [cited by applicant]
Guan, J., et al., “The U4 Antibody Epitope on Human Papillomavirus 16 Identified by Cryo-electron Microscopy” pp. 12108-12117. Journal of Virology. vol. 89, No. 23. Sep. 23, 2015, abstract; Genbank supplement, pp. 1-3; … [cited by applicant]
Guo et al., “Protein tolerance to random amino acid change”, Proc Natl Acad Sci USA. Jun. 22, 2004; 101(25): 9205-10. Epub Jun. 14, 2004. [cited by applicant]
Guo, H-F. et al., “Neuropilin functions as an essential cell surface receptor,” J. Biol. Chem. 290(49):29120-29126 (2015). [cited by applicant]
Harding, J. et al., “Lymphangiogenesis is induced by mycobacterial granulomas via vascular endothelial growth factor receptor-3 and supports systemic T-Cell responses against mycobacterial antigen,” Am. J. Path. 185(2):… [cited by applicant]
Henno, A. et al., “Altered expression of angiogenesis and lymphangiogenesis markers in the uninvolved skin of plaque-type psoriasis,” Br. J. Derm., 160:581-590 (2009). [cited by applicant]
Hey-Cunningham, A. J. et al., “Dysregulation of vascular endothelial growth factors and their neuropilin receptors in the eutopic endometrium of women with endometriosis,” Repro. Sci., Nov. 2013, vol. 20, No. 11, pp. 13… [cited by applicant]
Huang, Z-L. et al., “Establishment of a bead-based duplex assay for the simultaneous quantitative detection of Neuropilin-1 and Neuropilin-2 using xMAP technology and its clinical application,” J. Clin. Lab. Anal., 2019… [cited by applicant]
Immormino, R. M. et al., “Neuropilin-2 regulates airway inflammatory responses to inhaled lipopolysaccharide,” Am J Physiol Lung Cell Mol Physiol., 315(2):L202-L211 (Aug. 2018). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/026128, mailed Aug. 12, 2019, 12 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/054017, mailed Feb. 25, 2021, 13 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/078780 dated Mar. 15, 2023, 18 pages. [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2023/063208 dated Jul. 18, 2023, 11 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2021/021148 Jul. 28, 2021, 12 pages. [cited by applicant]
Karkkainen, M. J. et al., “A model for gene therapy of human hereditary lymphedema,” PNAS 98(22):12677-12682 (2001). [cited by applicant]
Karpanen, T. et al., “Functional interaction of VEGF-C and VEGF-D with neuropilin receptors,” The FASEB J. 20(9):1462-1472 (2007). [cited by applicant]
Li, J., et al., “Repertoire diversification in mice with an IgH-locus-targeted transgene for the 1-3 rearranged VH domain of a physiologically selected anti-ssDNA antibody,” Molecular Immunology. Mar. 5, 2005, vol. 42, … [cited by applicant]
Lippow, et al., “Computational design of antibody-affinity improvement beyond in vivo maturation,” Nat Biotechnol. (Oct. 2007); 25(10): 1171-1176. Epub Sep. 23, 2007. [cited by applicant]
Liu, B. et al., “Identification of prognostic biomarkers by combined mRNA and miRNA expression microarray analysis in pancreatic cancer,” Trans. Onc. 11(3):700-714 (2018). [cited by applicant]
Lu, Y. et al., “Identification of circulating neuropilin-1 and dose-dependent elevation following anti-neuropilin-1 antibody administration,” mAbs, 1(4):364-369 (2009). [cited by applicant]
MacCallum, R.M., et al., “Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography,” Journal of Molecular Biology, Oct. 11, 1996, vol. 262, No. 5, pp. 732-745. [cited by applicant]
Makinen, T. et al., “Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3,” Nature Med. 7(2):199-205 (2001). [cited by applicant]
Matthews, B. W., “Structural and genetic analysis of protein stability,” Annu. Rev. Biochem., 62:139-160 (1993). [cited by applicant]
Mendes-Da-Cruz, D. A. et al., “Semaphorin 3F and Neuropilin-2 Control the Migration of Human T-Cell Precursors,” PloS One 9(7), 7 pages (2014). [cited by applicant]
Mercurio, A. M., “VEGF/Neuropilin signaling in cancer stem cells,” Int. J. Mol. Sci., 20(3):490 (2019). [cited by applicant]
Meyer, L. A. T. et al., “Current drug design to target the semaphorin/neuropilin/plexin complexes,” Cell Adhes. & Migration 10(6):700-708 (2016). [cited by applicant]
Miaskowski, C. et al., “Lymphatic and angiogenic candidate genes predict the development of secondary lymphedema following breast cancer surgery,” PloS One 8(4), e60164, 20 pages (2013). [cited by applicant]
Moran, T. P. et al., “Neuropilin-2 is a negative regulator of allergic airway inflammation,” J. Allergy Clin. Immunol., AB180 Abstracts, 568 (Feb. 2018). [cited by applicant]
Mucka, P. et al., “Inflammation and lymphedema are exacerbated and prolonged by neuropilin 2 deficiency,” Am. J. Path. 186(11):2803-2812 (2016). [cited by applicant]
Nakayama, H. et al., “Regulation of mTOR signalling by semaphorin 3F-neuropilin 2 interactions in vitro and in vivo,” Scientific Reports 5, 11789, 14 pages (2015). [cited by applicant]
Napolitano, V. et al., “Neuropilins controlling cancer therapy responsiveness,” Int. J. Mol. Sci., 20(8):2049 (2019). [cited by applicant]
Nasarre, P. et al., “Semaphorin SEMA3F and VEGF have opposing effects on cell attachment and spreading,” Neoplasia 5(1):83-92 (2003). [cited by applicant]
Nasarre, P. et al., “The emerging role of class-3 semaphorins and their neuropilin receptors in oncology,” Oncotargets and Therapy 7:1663-1687 (2014). [cited by applicant]
Neufeld, G. et al., “Semaphorins in angiogenesis and tumor progression,” Cold Spring Harbor Perspect in Med. 2, 13 pages, a006718 (2012). [cited by applicant]
NG and Henikoff, “Predicting the Effects of Amino Acid Substitutions on Protein Function”. Annu Rev Genomics Hum Genet. (2006); 7: 61-80. [cited by applicant]
NG, T. et al., “Neuropilin 2 signaling is involved in cell positionig of adult-born neurons through glycogen synthase kinase-3,” J.Biol.Chem. 291(48):25088-25095 (2016). [cited by applicant]
Niland, S. et al., “Neuropilins in the context of tumor vasculature,” Int. J. Mol. Sci., 20(3):639 (2019). [cited by applicant]
Ogata, F. et al., “Excess lymphangiogenesis cooperatively induced by macrophages and CD4+ T cells drives the pathogenesis of lymphedema,” J. Inves. Derm. 136:706-714 (2016). [cited by applicant]
Papadopoulou, K. et al., “Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers,” Am. J. Cancer Res. 8(1):2-15 (2018). [cited by applicant]
Parker, M. W. et al., “Furin processing of semaphorin 3F determines its anti-angiogenic activity by regulating direct binding and competition for neuropilin,” Biochemistry 49(19):4068-4075 (2010). [cited by applicant]
Parker, M. W. et al., “Microplate-based screening for small molecule inhibitors of Neuropilin-2/VEGF-C interactions,” Anal. Biochem. 453:4-6 (May 2014). [cited by applicant]
Parker, M. W. et al., “Structural basis for VEGF-C binding to neuropilin-2 and sequestration by a soluble splice form,” Structure, 23(4):677-687 (2015). [cited by applicant]
Partial European Search Report for European Application No. EP20870841.2, dated Oct. 5, 2023, 15 pages. [cited by applicant]
Pavlakovic, H., “Soluble VEGFR2: an anti-lymphatic variant of VEGF receptors,” Ann. N.Y. Acad. Sci 1207(Suppl 1):E7-E15 (2010). [cited by applicant]
Pellet-Many, C. et al., “Neuropilins: structure, function and role in disease,” Biochemical Journal, vol. 411, No. 2, Apr. 2008, pp. 211-226. [cited by applicant]
Prud'homme, G. J. et al., “Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity,” Oncotarget 3(9):921-939 (2012). [cited by applicant]
Raaben, M. et al., “NRP2 and CD63 are host factors for Lujo virus cell entry,” Cell Host Microbe 22(5):688-695.e5 (2017). [cited by applicant]
Rey-Gallardo, A. et al., “Polysialylated neuropilin-2 enhances human dendritic cell migration through the basic C-terminal region of CCL21,” Glycobiology 20(9):1139-1146 (2010). [cited by applicant]
Rizzolio, S. et al., “Downregulating neuropilin-2 triggers a novel mechanism enabling EGFR-dependent resistance to oncogene-targeted therapies,” Cancer. Res. 78(4):1058-1068 (2017). [cited by applicant]
Rollenhagen, M. et al., “Polysialic acid on neuropilin-2 is exclusively synthesized by the polysialytransferase ST8SialV and attached to mucin-type O-glycans located between the b2 and c domain,” The J. Biol. Chem. 288(… [cited by applicant]
Roy, S. et al., “Multifaceted role of neuropilins in the immune system: Potential targets for immunotherapy,” Front. Immunol., Oct. 10, 2017, vol. 8, p. 1228. [cited by applicant]
Rudikoff, S., et al., “Single amino acid substitution altering antigen-binding specificity,” Proceedings of the National Academy of Sciences, 1982; 79(6): 1979-1983. [cited by applicant]
Saban, M. R. et al., “VEGF signaling mediates bladder neuroplasticity and inflammation in response to BCG,” BMC Physiology, 11(16):1-20 (2011). [cited by applicant]
Saban, R. “Angiogenic factors, bladder neuroplasticity and interstitial cystitis-new pathobiological insights,” Trans. Androl. Urol. 4(5):555-562 (2015). [cited by applicant]
Sainz-Jaspeado, M. et al., “Cytokines regulating lymphangiogenesis,” Curr. Opin. Immunol. 53:58-63 (2018). [cited by applicant]
Samuel, S., et al., “Neuropilin-2 Mediated [beta]-Catenin Signaling and Survival in Human Gastro-Intestinal Cancer Cell Lines,” PLOS One, vol. 6, No. 10, Oct. 20, 2011, 11 pages, e23208, DOI: 10.1371/journal.pone.002320… [cited by applicant]
Sarabipour, S. et al., “VEGF-A121a binding to Neuropilins—A concept revisited,” Cell Adhes. & Migration 12(3):204-214 (2018). [cited by applicant]
Schellenburg, S. et al., “Role of neuropilin-2 in the immune system,” Molecular Immunology, 90:239-244 (2017). [cited by applicant]
Schwarz, Q. et al., “Neuropilin, you gotta let me know, Should I stay or should I go?” Cell Adhesion & Migration 4(1):61-66 (2010). [cited by applicant]
Simeon et al., “In vitro-engineered non-antibody protein therapeutics,” Protein Cell 2018, 9(1 ):3-14, doi:1 0.1 007/s13238-017-0386-6. [cited by applicant]
Stanton, M. J. et al., “Angiogenic growth factor axis in autophagy regulation,” Autophagy 9(5):789-790 (2013). [cited by applicant]
Stine, M. J. et al., “Integration of genotypic and phenotypic screening reveals molecular mediators of melanoma-stromal interaction,” Cancer. Res. 71(7):2433-2444 (Apr. 2011). [cited by applicant]
Sulpice, E. et al., “Neuropilin-1 and neuropilin-2 act as coreceptors, potentiating proangiogenic activity,” Blood 111(4):2036-2045 (2008). [cited by applicant]
Tu, D-G. et al., “Promotion of metastasis of thyroid cancer cells via NRP-2 mediated induction,” Oncol. Lett. 12:4224-4230 (2016). [cited by applicant]
Uni Prot Database, P01857, IGHG1_Human, Retrieved online:< url: https://www.uniprot.org/uniprotkb/P01857/entry#structure, Retrieved on Jan. 12, 2023, pp. 1, 2 and 11 , 2023. [cited by applicant]
UniProtKB Accession No. A0A1C0YHR0, Uncharacterized protein, Nov. 2, 2016 [online] 1-3; [Retrieved on May 15, 2023]. Retrieved from the internet: URL: https://www.uniprot.org/uniprot/A0A1COYHR0 Entire document; amino ac… [cited by applicant]
Vaahtomeri, K. et al., “Lymphangiogenesis guidance by paracrine and pericellular factors,” Genes & Dev 31:1615-1634 (2017). [cited by applicant]
Vasquez, E. et al., “Deletion of neuropilin 2 enhances detrusor contractility following bladder outlet obstruction,” JCI Insight 2(3):e90617, 10 pages (2017). [cited by applicant]
Verlinden, L. et al., “Nrp2 deficiency leads to trabecular bone loss and is accompanied by enhanced osteoclast and reduced osteoblast numbers,” Bone 55:465-475 (2013). [cited by applicant]
Wang, J. et al., “NRP-2 in tumor lymphangiogenesis and lymphatic metastasis,” Cancer. Lett. 418:176-184 (2018). [cited by applicant]
Werneburg, S. et al., “Polysialylation and lipopolysaccharide-induced shedding of E-selectin ligand-1 and neuropilin-2 by microglia and THP1 macrophages,” GLIA 64:1314-1330 (2016). [cited by applicant]
Wild, J. R. L. et al., “Neuropilins: expression and roles in the epithelium,” Int. J. Exp. Path. 93:81-103 (2012). [cited by applicant]
Wittmann, P. et al., Neuropilin-2 induced by transforming growth factor-augments migration of hepatocellular carcinoma cells, BMC Cancer, 2015, vol. 15, No. 1, pp. 1-8. [cited by applicant]
Wu, H., et al., “Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues”, Journal of Molecular Biology (1999); 294(1): 151-162. [cited by applicant]
Xu, Y. et al., “Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3,” J. Cell. Biol. 188(1):115-130 (2010). [cited by applicant]
Yang, F. et al., “Understanding lyphangiogenesis in knockout models, the cornea, and ocular diseases for the development of therapeutic interventions,” Surv. Ophthalmol., 61(3):272-296 (May-Jun. 2016). [cited by applicant]
Yang, Y. et al., “Preparation, Purification, and Identification of a Monoclonal Antibody Against NRP2 b1b2 Domain,” Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, vol. 34, No. 5, Oct. 2015, pp. 354-359. [cited by applicant]
Yasuoka, H. et al., “Neuropilin-2 expression in breast cancer: correlation with lymph node metastasis, poor prognosis, and regulation of CXCR4 expression,” BMC Cancer, Dec. 2009, vol. 9, pp. 1-7. [cited by applicant]
Yelland, T. et al., “Crystal structure of the neuropilin-1 MAM domain: completing the neuropilin-1 ectodomain picture,” Structure 24(11):2008-2015 (2016). [cited by applicant]
Yuan, L. et al., “Abnormal lymphatic vessel development in neuropilin 2 mutant mice,” Development 129:4797-4806 (2002). [cited by applicant]
Zhu, H. et al., “VEGF-C inhibition reverses resistance of bladder cancer cells to cisplatin via upregulating maspin,” Mol. Med. Reports, 2015, vol. 12, pp. 3163-3169. [cited by applicant]
Extended European Search Report for European Application No. EP20870841.2, mailed on Jan. 11, 2024, 12 pages. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2022/078780, mailed Apr. 30, 2024, 13 pages. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2023/063208, mailed Sep. 6, 2024 7 pages. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2023/068511, mailed Dec. 26, 2024, 8 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2023/068511, mailed on Jan. 10, 2024, 12 pages. [cited by applicant]
Lambrinos, G. et al., “Neuropilin 2 is a novel regulator of distal colon contractility,” Am. J. Pathol., Nov. 2022, vol. 192, No. 11, pp. 1592-1603. [cited by applicant]
Pan et al., “Molecular mechanisms for tumor resistance to chemotherapy,” Clinical and Experimental Pharmacology and Physiology, Aug. 2016, vol. 43, No. 8, pp. 723-737. [cited by applicant]
Salahuddin et al, “Pulmonary Eosinophilia,” NIH Bookshelf, last updated May 22, 2023, in: StatPearls, Treasure Island (FL): StatPearls Publishing, 8 pages, at url: https://www.ncbi.nlm.nih.gov/books/NBK470600/. [cited by applicant]